Publications by authors named "Somasekhar Konduru"
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.
Michael Schenker Mauricio Burotto Martin Richardet Tudor-Eliade Ciuleanu Anthony Gonçalves Somasekhar Konduru
J Immunother Cancer
August 2024
Article Synopsis
- Checkpoint inhibitor therapy, particularly nivolumab combined with ipilimumab, shows promise for patients with high tumor mutational burden (TMB-H) across various tumor types, indicating a potential survival benefit.
- The study involved 201 patients with advanced solid tumors who were resistant to standard treatments; they were randomly assigned to receive either the combination of nivolumab and ipilimumab or nivolumab alone, with the effectiveness measured based on objective response rates.
- Results demonstrated higher response rates in patients with TMB-H tumors who received the combination therapy, and the safety profile was acceptable, suggesting this treatment could be beneficial for patients with limited options.
Objectives: Arachidonic acid-derived eicosanoids (lipoxins and 15-epilipoxins) have a major role in resolution of inflammation. 15-epi-lipoxin A(4) (15-epi-LXA(4)) is a lipid mediator with strong anti-inflammatory and inflammation-resolving effects. We examined the effect of pioglitazone therapy on plasma 15-epi-LXA(4) in patients with type 2 diabetes (T2DM).
View Article and Find Full Text PDF